Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Century Therapeutics Inc (IPSC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IPSC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 2.2% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.88M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 496770 | Beta 1.75 | 52 Weeks Range 0.45 - 4.43 | Updated Date 04/1/2025 |
52 Weeks Range 0.45 - 4.43 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date 2025-03-20 | When - | Estimate -0.4375 | Actual -0.3542 |
Profitability
Profit Margin - | Operating Margin (TTM) -822.26% |
Management Effectiveness
Return on Assets (TTM) -23.67% | Return on Equity (TTM) -73.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -96586856 | Price to Sales(TTM) 6.7 |
Enterprise Value -96586856 | Price to Sales(TTM) 6.7 | ||
Enterprise Value to Revenue 1.96 | Enterprise Value to EBITDA 0.08 | Shares Outstanding 86045000 | Shares Floating 39812176 |
Shares Outstanding 86045000 | Shares Floating 39812176 | ||
Percent Insiders 27.48 | Percent Institutions 57.26 |
Analyst Ratings
Rating 4.43 | Target Price 8.33 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Century Therapeutics Inc
Company Overview
History and Background
Century Therapeutics Inc. was founded in 2018. The company focuses on developing allogeneic cell therapies for cancer, leveraging induced pluripotent stem cells (iPSCs) to engineer immune cells.
Core Business Areas
- Allogeneic Cell Therapies: Develops off-the-shelf cell therapies for various cancers.
- iPSC Platform: Utilizes its iPSC platform to generate and engineer immune cells.
- Oncology: Focuses exclusively on oncology indications, targeting solid tumors and hematological malignancies.
Leadership and Structure
Lalo Flores is the CEO. The company has a management team with expertise in cell therapy, immunology, and drug development. Board of Directors includes experienced biotech investors and executives.
Top Products and Market Share
Key Offerings
- CNT-416: An iPSC-derived CAR-iNK cell therapy targeting CD19+ malignancies. Currently in Phase 1 clinical trials. Competitors include autologous CAR-T therapies from companies like Kite (GILD) and Novartis (NVS) and allogeneic CAR-T therapies from companies such as Allogene (ALLO).
- CNT-702: An iPSC-derived CAR-iMNKT cell therapy targeting solid tumors expressing MUC16. Currently in preclinical development. Competitors include companies developing other MUC16-targeting therapies.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by the increasing prevalence of cancer and the promise of personalized medicine. The allogeneic cell therapy segment is attracting significant investment due to its potential to overcome limitations of autologous approaches.
Positioning
Century Therapeutics is positioned as a leader in the allogeneic cell therapy space, leveraging its iPSC platform for scalability and engineering capabilities. Their competitive advantage lies in their ability to generate and modify immune cells from a renewable source.
Total Addressable Market (TAM)
The global cell therapy market is estimated to reach hundreds of billions of dollars in the coming years. Century Therapeutics is positioned to capture a portion of this TAM with its allogeneic cell therapies targeting various cancer indications.
Upturn SWOT Analysis
Strengths
- Proprietary iPSC platform
- Strong scientific expertise
- Potential for off-the-shelf cell therapies
- Focus on oncology
- Innovative approach to cell engineering
Weaknesses
- Early-stage clinical programs
- High cash burn rate
- Dependence on clinical trial success
- Complex manufacturing processes
- Intense competition
Opportunities
- Expanding pipeline of cell therapies
- Partnerships with pharmaceutical companies
- Advancements in cell engineering technologies
- Positive clinical trial results
- Addressing unmet medical needs in cancer
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cell therapy companies
- Manufacturing challenges
- Adverse events in patients
Competitors and Market Share
Key Competitors
- ALLO
- NK
- CRSP
Competitive Landscape
Century Therapeutics faces intense competition from established cell therapy companies and emerging players. Its iPSC platform provides a potential advantage in terms of scalability and engineering, but it needs to demonstrate clinical efficacy to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by pre-clinical development and initial clinical trials. Revenue is currently negligible.
Future Projections: Future growth is dependent on clinical trial success and potential partnerships. Analyst estimates vary, but project significant revenue potential if clinical programs are successful.
Recent Initiatives: Advancement of CNT-416 into Phase 1 trials. Continued development of iPSC platform and expansion of preclinical pipeline.
Summary
Century Therapeutics is an early-stage biotech company pioneering allogeneic cell therapies for cancer using iPSC technology. Its strength lies in its innovative platform and focus on oncology. The company needs to demonstrate clinical efficacy and manage its high cash burn. Success is heavily reliant on navigating clinical trials and competition.
Similar Companies
- ALLO
- NK
- CRSP
- GILD
- BMY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Century Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-06-18 | CEO & Director Mr. Brent Pfeiffenberger M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.centurytx.com |
Full time employees 140 | Website https://www.centurytx.com | ||
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.